forward to a collegeForward to a Colleague
Home>Resources for My Patients>Chronic Pain>Counseling FAQs

Counseling FAQs

Below is a sampling of questions and answers you may want to use when counseling your patients who are prescribed NUCYNTA® ER. This series of questions and answers may not provide the specific information you are looking for; if this is the case, please see the full Prescribing Information and Medication Guide for more information. Please encourage your patients to refer to the Medication Guide for a full list of questions. In addition, you may also contact the Medical Information Center at 1-800-JANSSEN (Monday-Friday, 9 am-5 pm ET).

What is NUCYNTA® ER?

NUCYNTA® ER is a prescription medication that contains the opioid narcotic tapentadol. It is used to manage moderate to severe chronic pain in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

Return to top

Is there a way to make NUCYNTA® ER more affordable?

Yes. With the NUCYNTA® ER Pay No More Than $25 Savings Card, available here, patients with commercial insurance will pay no more than $25 for their NUCYNTA® ER prescription, with a maximum benefit amount of $100. Your savings card is valid for up to 14 prescriptions per calendar year (not to exceed 12 uses at the same dose). Some restrictions apply. See Eligibility Criteria on the savings card. Additional patient assistance programs can be found on www.access2wellness.com.

Return to top

Does my pharmacy carry NUCYNTA® ER?

NUCYNTA® ER should be available at most pharmacies. However, if you are experiencing difficulty locating a pharmacy that can fill a prescription for NUCYNTA® ER, you can use the pharmacy locator to find a local participating pharmacy in the United States (and Puerto Rico). Not all pharmacies may be identified. Contact your local pharmacy for availability. Please be advised that not all retail pharmacies participate in this locator service. Please call ahead to your pharmacy to confirm the availability of NUCYNTA® ER.

Return to top

How do I take NUCYNTA® ER?

Take NUCYNTA® ER exactly as prescribed by your healthcare professional. Do not change the dose unless your healthcare professional tells you to. Your healthcare professional may change your dose after seeing how the medicine affects you. You can take NUCYNTA® ER with or without food.

Swallow NUCYNTA® ER whole. You must take NUCYNTA® ER one tablet at a time, with enough water to make sure that you completely swallow the tablet right away. Do not soak, lick, or wet the tablet before putting it in your mouth. Do not break, split, chew, dissolve, or crush NUCYNTA® ER tablets before swallowing, or inject the contents. If you cannot swallow tablets, tell your healthcare professional.

If you miss a dose, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at the same time unless your healthcare professional tells you to. If you are not sure about your dosing, call your healthcare professional. If you take too much NUCYNTA® ER or overdose, get emergency help right away.

Call your healthcare professional if your pain is not well controlled while taking NUCYNTA® ER. Follow your healthcare professional's instructions about how to slowly stop taking NUCYNTA® ER to prevent uncomfortable withdrawal symptoms.

Return to top

What's the highest dose of NUCYNTA® ER that can safely be used?

The maximum total daily dose of NUCYNTA® ER is 500 mg, which would be taken as 250 mg twice daily. Do not exceed a total daily dose of NUCYNTA® ER of 500 mg.

Return to top

Can NUCYNTA® ER tablets be split or crushed?

Do not break, split, chew, dissolve, or crush NUCYNTA® ER tablets before swallowing, or inject the contents. Taking split, broken, chewed, dissolved, or crushed NUCYNTA® ER tablets could lead to rapid release and absorption of a potentially fatal dose of tapentadol. The NUCYNTA® ER formulation was designed to not be amenable to crushing or dissolution.

Return to top

How often will I need to take NUCYNTA® ER?

NUCYNTA® ER is taken twice daily, approximately every 12 hours, at the dose prescribed by your healthcare professional.

Return to top

What are the most common side effects of NUCYNTA® ER?

The most common side effects with NUCYNTA® ER are:

  • nausea
  • constipation
  • headache
  • dizziness
  • sleepiness

These are not all the possible side effects of NUCYNTA® ER. For a complete list, ask your healthcare professional or pharmacist. Talk to your healthcare professional if you have any side effect that bothers you or that does not go away.

You may report side effects to the US Food and Drug Administration (FDA) at 1-800-FDA-1088.

Return to top

Can I take NUCYNTA® ER on an empty stomach?

Yes, NUCYNTA® ER may be taken with or without food.

Return to top

Is it safe for me to drink alcohol while taking NUCYNTA® ER?

No. You must not consume alcoholic beverages, or prescription or nonprescription medications containing alcohol. Co-ingestion of alcohol with NUCYNTA® ER may result in a potentially fatal overdose of tapentadol.

Return to top

If I am taking other medications, such as antidepressants, and received a prescription for NUCYNTA® ER, should I be concerned?

Tell your healthcare professional about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Some medicines may cause serious or life-threatening medical problems when taken with NUCYNTA® ER. The doses of certain other medicines and NUCYNTA® ER sometimes need to be changed. Your healthcare professional can tell you what medicines can be safely taken with NUCYNTA® ER.

Especially tell your healthcare professional if you take:

  • Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), tricyclic antidepressants, tramadol, and triptan medicines.
  • Other medicines that make you sleepy such as:
    • other pain medicines
    • antidepressant medicines, including those listed above
    • sleeping pills
    • antihistamines
    • anti-anxiety medicines
    • muscle relaxants
    • anti-nausea medicines
    • tranquilizers

Do not take NUCYNTA® ER if you take a monoamine oxidase inhibitor (MAOI) medicine.

Return to top

Can I take NUCYNTA® ER in combination with NUCYNTA® or tramadol?

No, you should stop taking all other tapentadol and tramadol products when beginning and while taking NUCYNTA® ER.

Return to top

Can I take NUCYNTA® ER with acetaminophen?

In clinical studies with NUCYNTA® ER, patients were allowed to take acetaminophen at certain points during the studies. Acetaminophen was also given to patients taking NUCYNTA® ER in drug interaction studies, and there were no significant findings. Note that there is no acetaminophen in NUCYNTA® ER.

Return to top

Should I be worried about becoming addicted to, or dependent on, NUCYNTA® ER?

All opioids carry some risk of addiction/dependence; however, concerns about abuse and addiction should not prevent the proper management of pain. There is a chance of abuse or addiction with NUCYNTA® ER. The chance is higher if you are or have been addicted to or abused other medicines, street drugs, or alcohol, or if you have a history of mental problems. Do not stop taking NUCYNTA® ER or any other opioid without talking to your healthcare professional. You could become sick with uncomfortable withdrawal symptoms because your body has become used to these medicines. Physical dependence is not the same as drug addiction. Your healthcare professional can tell you more about the difference between physical dependence and drug addiction.

Return to top

Can I drive while taking NUCYNTA® ER?

Do not drive, operate machinery, or engage in other dangerous activities until you know how you react to this medicine. NUCYNTA® ER can make you sleepy.

Return to top

If I stop taking NUCYNTA® ER, will I go through withdrawal?

Withdrawal symptoms may occur if you stop taking NUCYNTA® ER abruptly. Do not stop taking NUCYNTA® ER without talking to your healthcare professional. Your healthcare professional can work with you to gradually reduce the dose of NUCYNTA® ER, which may help reduce withdrawal symptoms.

Return to top

My healthcare professional requires that I undergo periodic drug screening. Will NUCYNTA® ER show up on my screening test?

Drug screening tests are currently available that can confirm the presence of tapentadol in urine. For information about laboratories that screen for tapentadol, call 1-800-NUCYNTA (1-800-682-9682).

Return to top

Can I take NUCYNTA® ER if I have liver problems (hepatic impairment)?

NUCYNTA® ER should be used with caution in patients with moderate hepatic impairment. Since NUCYNTA® ER has not been studied in patients with severe hepatic impairment, you should not use it if your liver problems are considered severe.

Return to top

Can I take NUCYNTA® ER if I have kidney problems (renal impairment)?

NUCYNTA® ER is not recommended in patients with severe renal impairment.

Return to top

Can I take NUCYNTA® ER if I am pregnant or planning to become pregnant?

NUCYNTA® ER should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Return to top
 

For the management of moderate to severe chronic pain in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time

NUCYNTA® ER IMPORTANT SAFETY INFORMATION

WARNING: POTENTIAL FOR ABUSE, PROPER PATIENT SELECTION, AND LIMITATIONS OF USE


Potential for Abuse

NUCYNTA® ER contains tapentadol, a mu-opioid agonist and a Schedule II controlled substance with an abuse liability similar to other opioid analgesics.


NUCYNTA® ER can be abused in a manner similar to other opioid agonists, legal or illicit. These risks should be considered when prescribing or dispensing NUCYNTA® ER in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Schedule II opioid substances, which include hydromorphone, morphine, oxycodone, fentanyl, oxymorphone, and methadone, have the highest potential for abuse and risk of fatal overdose due to respiratory depression.


Proper Patient Selection

NUCYNTA® ER is an extended-release formulation of tapentadol indicated for the management of moderate to severe chronic pain in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.


Limitations of Use

NUCYNTA® ER is not intended for use as an as-needed analgesic.


NUCYNTA® ER is not intended for the management of acute or postoperative pain.


NUCYNTA® ER tablets are to be swallowed whole and are not to be split, broken, chewed, dissolved, or crushed. Taking split, broken, chewed, dissolved, or crushed NUCYNTA® ER tablets could lead to rapid release and absorption of a potentially fatal dose of tapentadol.


Patients must not consume alcoholic beverages, or prescription or nonprescription medications containing alcohol. Co-ingestion of alcohol with NUCYNTA® ER may result in a potentially fatal overdose of tapentadol.


CONTRAINDICATIONS

  • NUCYNTA® ER is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma or hypercapnia in unmonitored settings or in the absence of resuscitative equipment.
  • NUCYNTA® ER is contraindicated in any patient who has or is suspected of having a paralytic ileus.
  • NUCYNTA® ER is contraindicated in patients who are receiving monoamine oxidase inhibitors (MAOIs) or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels, which may result in adverse cardiovascular events.
  • NUCYNTA® ER is contraindicated in patients with a known hypersensitivity to the active substance, tapentadol, or any component of the product. Angioedema has been reported in association with use of tapentadol.

WARNINGS and PRECAUTIONS

  • NUCYNTA® ER tablets are to be swallowed whole and are not to be split, broken, chewed, dissolved, or crushed. Taking split, broken, chewed, crushed, or dissolved NUCYNTA® ER tablets leads to the rapid release and absorption of a potentially fatal dose of tapentadol.
  • NUCYNTA® ER tablets must be kept in a secure place out of the reach of children. Accidental consumption of NUCYNTA® ER, especially in children, can result in a fatal overdose of tapentadol.
  • Respiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation.
  • Use NUCYNTA® ER with caution in patients with conditions accompanied by hypoxia, hypercapnia, or decreased respiratory reserve, such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, central nervous system (CNS) depression, or coma. In such patients, even usual therapeutic doses of NUCYNTA® ER may increase airway resistance and decrease respiratory drive to the point of apnea. Alternative non–mu-opioid agonist analgesics should be considered, and NUCYNTA® ER should be employed only under careful medical supervision at the lowest effective dose in such patients. If respiratory depression occurs, it should be treated as any mu-opioid agonist-induced respiratory depression.
  • Patients receiving other opioid agonist analgesics, general anesthetics, phenothiazines, other tranquilizers, sedatives, hypnotics, centrally acting muscle relaxants, or other CNS depressants (including alcohol) concomitantly with NUCYNTA® ER may exhibit additive CNS depression. Interactive effects resulting in respiratory depression, hypotension, profound sedation, coma, or death may result if these drugs are taken in combination with NUCYNTA® ER. When such combined therapy is contemplated, a dose reduction of one or both agents should be considered.
  • Opioid analgesics can raise cerebrospinal fluid pressure as a result of respiratory depression with carbon dioxide retention. Therefore, NUCYNTA® ER should not be used in patients who may be susceptible to the effects of raised cerebrospinal fluid pressure, such as those with evidence of head injury and increased intracranial pressure. Opioid analgesics may obscure the clinical course of patients with head injury due to effects on pupillary response and consciousness. NUCYNTA® ER should be used with caution in patients with head injury, intracranial lesions, or other sources of preexisting increased intracranial pressure.
  • Tapentadol is a mu-opioid agonist and is a Schedule II controlled substance. Such drugs are sought by drug abusers and people with addiction disorders. Diversion of Schedule II products is an act subject to criminal penalty.
  • Patients should be assessed for their clinical risks for opioid abuse or addiction prior to being prescribed opioids.
  • NUCYNTA® ER can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing NUCYNTA® ER in situations where the physician or pharmacist is concerned about an increased risk of misuse and abuse. Concerns about abuse and addiction should not prevent the proper management of pain. However, all patients treated with mu-opioid agonists require careful monitoring for signs of abuse and addiction, since use of mu-opioid agonist analgesic products carries the risk of addiction even under appropriate medical use.
  • Drug abusers may attempt to abuse NUCYNTA® ER by crushing, chewing, snorting, or injecting the product. These practices may result in the uncontrolled delivery of NUCYNTA® ER and pose a significant risk to the abuser that could result in overdose and death.
  • NUCYNTA® ER may cause severe hypotension. Patients at higher risk of hypotension include those with hypovolemia or those taking concurrent products that compromise vasomotor tone (eg, phenothiazines, general anesthetics).
  • Patients should be cautioned that NUCYNTA® ER may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. This is to be expected, especially at the beginning of treatment, at any change of dosage, as well as in combination with alcohol or tranquilizers.
  • NUCYNTA® ER may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause CNS depression, because respiratory depression, hypotension, hypertension, and profound sedation, coma, or death may result.
  • NUCYNTA® ER has not been evaluated in patients with a predisposition to a seizure disorder, and such patients were excluded from clinical studies. As with other opioids, NUCYNTA® ER should be prescribed with care in patients with a history of a seizure disorder or any condition that would put the patient at risk of seizures.
  • Cases of life-threatening serotonin syndrome have been reported with the concurrent use of tapentadol and serotonergic drugs. Serotonergic drugs comprise selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, drugs that affect the serotonergic neurotransmitter system (eg, mirtazapine, trazodone, and tramadol), and drugs that impair metabolism of serotonin (including MAOIs). This may occur within the recommended dose. Serotonin syndrome may include mental-status changes (eg, agitation, hallucinations, coma), autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (eg, hyperreflexia, incoordination) and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea), and can be fatal.
  • Withdrawal symptoms may occur if NUCYNTA® ER is discontinued abruptly. These symptoms may include: anxiety, sweating, insomnia, rigors, pain, nausea, tremors, diarrhea, upper respiratory symptoms, piloerection, and rarely, hallucinations. Withdrawal symptoms may be reduced by tapering NUCYNTA® ER.
  • A study with the immediate-release formulation of tapentadol in subjects with hepatic impairment showed higher serum concentrations of tapentadol than in those with normal hepatic function. Tapentadol should be used with caution in patients with moderate hepatic impairment.
  • NUCYNTA® ER has not been studied in patients with severe hepatic impairment, and use in this population is not recommended.
  • Like other drugs with mu-opioid agonist activity, NUCYNTA® ER may cause spasm of the sphincter of Oddi and should be used with caution in patients with biliary tract disease, including acute pancreatitis.
  • NUCYNTA® ER should be used with caution in the following conditions: adrenocortical insufficiency (eg, Addison's disease); delirium tremens; myxedema or hypothyroidism; prostatic hypertrophy or urethral stricture; and toxic psychosis.
  • Pregnancy Category C. There are no adequate and well-controlled studies of NUCYNTA® ER in pregnant women. NUCYNTA® ER should be used during pregnancy ONLY if the potential benefit justifies the potential risk to the fetus.

ADVERSE REACTIONS

  • The most common (≥10%) adverse reactions were nausea, constipation, headache, dizziness, and somnolence.

For the relief of moderate to severe acute pain in patients 18 years of age
or older

NUCYNTA® IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • Like other drugs with mu-opioid agonist activity, NUCYNTA® is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma or hypercapnia in unmonitored settings or in the absence of resuscitative equipment. NUCYNTA® is contraindicated in patients who have or are suspected to have paralytic ileus. NUCYNTA® is also contraindicated in patients currently using or within 14 days of using monoamine oxidase inhibitors (MAOIs) due to potential additive effects on norepinephrine levels, which may result in adverse cardiovascular events.

WARNINGS & PRECAUTIONS

  • Respiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation. NUCYNTA® should be administered with caution to the elderly, debilitated patients, and patients with conditions accompanied by hypoxia, hypercapnia or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, CNS depression, or coma. In such patients, even usual therapeutic doses of NUCYNTA® may increase airway resistance and decrease respiratory drive to the point of apnea. Alternative non-mu-opioid agonist analgesics should be considered and NUCYNTA® should be employed only under careful medical supervision at the lowest effective dose in such patients. If respiratory depression occurs, it should be treated as any mu-opioid agonist-induced respiratory depression.
  • Patients receiving other mu-opioid agonist analgesics, general anesthetics, phenothiazines, other tranquilizers, sedatives, hypnotics, or other CNS depressants (including alcohol) concomitantly with NUCYNTA® may exhibit additive CNS depression. Interactive effects resulting in respiratory depression, hypotension, profound sedation, coma or death may result if these drugs are taken in combination with NUCYNTA®. When such combined therapy is contemplated, a dose reduction of one or both agents should be considered.
  • Opioid analgesics can raise cerebrospinal fluid pressure as a result of respiratory depression with carbon dioxide retention. Therefore, NUCYNTA® should not be used in patients susceptible to the effects of raised cerebrospinal fluid pressure such as those with head injury and increased intracranial pressure. Opioid analgesics may obscure the clinical course of patients with head injury due to effects on pupillary response and consciousness. NUCYNTA® should be used with caution in patients with head injury, intracranial lesions, or other sources of preexisting increased intracranial pressure.
  • NUCYNTA® is a mu-opioid agonist and is a Schedule II controlled substance. Such drugs are sought by drug abusers and people with addiction disorders. Diversion of Schedule II products is an act subject to criminal penalty. NUCYNTA® can be abused in a manner similar to other mu-opioid agonists, legal or illicit. This should be considered when prescribing or dispensing NUCYNTA® in situations where the physician or pharmacist is concerned about an increased risk of misuse and abuse. All patients treated with mu-opioid agonists require careful monitoring for signs of abuse and addiction. NUCYNTA® may be abused by crushing, chewing, snorting or injecting the product. These practices pose a significant risk to the abuser that could result in overdose and death.
  • Experience with NUCYNTA® overdose is very limited. Management of overdose should be focused on treating symptoms of mu-opioid agonism. Primary attention should be given to reestablishment of a patent airway and institution of assisted or controlled ventilation when overdose of NUCYNTA® is suspected. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation.
  • Patients should be cautioned that NUCYNTA® may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. This is to be expected especially at the beginning of treatment, at any change of dosage as well as in combination with alcohol or tranquilizers.
  • NUCYNTA® has not been systematically evaluated in patients with a seizure disorder, and such patients were excluded from clinical studies. NUCYNTA® should be prescribed with care in patients with a history of a seizure disorder or any condition that would put the patient at risk of seizures.
  • The development of a potentially life-threatening serotonin syndrome may occur with use of SNRI products, including NUCYNTA® , particularly with concomitant use of serotonergic drugs such as SSRIs, SNRIs, TCAs, MAOIs and triptans, and with drugs which impair metabolism of serotonin (including MAOIs). Serotonin syndrome may include mental-status changes (eg, agitation, hallucinations, coma), autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (eg, hyperreflexia, incoordination) and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea).
  • Withdrawal symptoms may occur if NUCYNTA® is discontinued abruptly. These symptoms may include: anxiety, sweating, insomnia, rigors, pain, nausea, tremors, diarrhea, upper respiratory symptoms, piloerection, and rarely, hallucinations. Withdrawal symptoms may be reduced by tapering NUCYNTA®.
  • Pregnancy Category C. There are no adequate and well-controlled studies of NUCYNTA® in pregnant women. NUCYNTA® should be used during pregnancy ONLY if the potential benefit justifies the potential risk to the fetus. NUCYNTA® is not recommended for use in women during and immediately prior to labor and delivery. Neonates whose mothers have been taking NUCYNTA® should be monitored for respiratory depression. NUCYNTA® should not be used during breastfeeding.
  • NUCYNTA® is not recommended in patients with severe renal or hepatic impairment. NUCYNTA® should be used with caution in patients with moderate hepatic impairment. Like other drugs with mu-opioid agonist activity, NUCYNTA® may cause spasm of the sphincter of Oddi and should be used with caution in patients with biliary tract disease, including acute pancreatitis.

ADVERSE REACTIONS

  • The most common adverse events are nausea, dizziness, vomiting, somnolence and headache.
Click here to go to Nucynta Section Click here to go to Nucynta-ER Section